Intranasal Oxytocin (IN-OXT) ( DrugBank: Oxytocin )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
193	Prader-Willi syndrome	2

193. Prader-Willi syndrome

---

Clinical trials : 111 /  Drugs : 120 - (DrugBank : 30) / Drug target genes : 51 - Drug target pathways : 103

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03197662 (ClinicalTrials.gov)	April 11, 2018	19/6/2017	Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome	Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Prader-Willi Syndrome;Hyperphagia	Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo	Montefiore Medical Center	NULL	Recruiting	5 Years	17 Years	All	50	Phase 2	United States
2	NCT02629991 (ClinicalTrials.gov)	October 2015	18/10/2015	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome	Prader-Willi Syndrome;Hyperphagia	Drug: Intranasal Oxytocin (IN-OXT);Drug: Matched Placebo	Montefiore Medical Center	Foundation for Prader-Willi Research	Unknown status	5 Years	18 Years	All	24	Phase 2	United States